Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $109.1 million.

  • Apellis Pharmaceuticals' Net Cash Flow rose 19781.37% to $109.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.3 million, marking a year-over-year increase of 24650.06%. This contributed to the annual value of $61.0 million for FY2024, which is 13034.79% up from last year.
  • According to the latest figures from Q3 2025, Apellis Pharmaceuticals' Net Cash Flow is $109.1 million, which was up 19781.37% from $11.0 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Net Cash Flow ranged from a high of $356.4 million in Q4 2021 and a low of -$298.4 million during Q1 2021
  • Moreover, its 5-year median value for Net Cash Flow was -$6.8 million (2022), whereas its average is -$4.4 million.
  • Over the last 5 years, Apellis Pharmaceuticals' Net Cash Flow had its largest YoY gain of 323338.72% in 2023, and its largest YoY loss of 71705.26% in 2023.
  • Apellis Pharmaceuticals' Net Cash Flow (Quarter) stood at $356.4 million in 2021, then plummeted by 109.14% to -$32.6 million in 2022, then plummeted by 212.59% to -$101.8 million in 2023, then soared by 115.07% to $15.3 million in 2024, then soared by 611.3% to $109.1 million in 2025.
  • Its last three reported values are $109.1 million in Q3 2025, $11.0 million for Q2 2025, and -$53.1 million during Q1 2025.